Genenta Science S.P.A.

Genenta Science SpA is a clinical-stage biotechnology company, which engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

Genenta's CEO to present at the U.S. Senate, Washington D.C.at the meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatl

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), marking a significant expansion of the potential applications for Genenta's flagship product, Temferon™. This approval by AIFA is in line with the standards that are harmonized across European regulatory frameworks established by the European Medicines Agency (EMA).

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Affimed

Anixa Biosciences Inc

FibroGen

Lipocine

Nuvectis Pharma

Relmada Therapeutics Inc

One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.

7 Penny Biotech Stocks to Triple Your Investment

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.

Genenta Welcomes New Directors John L. Cantello, Lauren H.

Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences.

Genenta to Present at Upcoming Scientific and Investor Conferences

Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the European Commission has granted Orphan Drug Designation (ODD) to Temferon ™ for the treatment of glioma. Glioblastoma Multiforme (GBM) is the first clinical indication of Temferon.

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced its fiscal year 2022 financial results and that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 (the “Annual Report”) with the Securities and Exchange Commission ("SEC"). The Annual Report can be accessed on the Company's investor relations website at  https://ir.genenta.com/financial-information/sec-filings  as well as the SEC's website at  http://www.sec.gov .

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the license agreement with Ospedale San Raffaele (OSR) has been amended and restated to provide access to all solid tumor indications, subject to governmental consent as described below.

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Temferon™ for the treatment of glioblastoma multiforme (GBM).

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs. AGC Biologics offers end-to-end global viral vector and cell therapy development, manufacturing and quality/regulatory services, supported by scientists with 30 years of knowledge and experience.

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

• Signs of intra-tumor pro-inflammatory state in patients• Temferon™ induced immune system reset in preclinical studies• Macrophage and T cell profiles in patients' tumor microenvironment echo preclinical findings

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), (“Genenta” or the “Company”), a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, provides business and financial results for the six months ended June 30, 2022.

Genenta Provides First Half 2022 Business Update and Financial Results

MILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at several upcoming investor conferences in September and October.

Genenta to Present at Upcoming Investor Conferences

Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets Think tank of Italian companies and entrepreneurs listed or to be listed on US capital markets

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be presenting at several upcoming scientific congresses in May and June.

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

Extensive experience in business development with AstraZeneca and GSK Extensive experience in business development with AstraZeneca and GSK

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission ("SEC") on May 2, 2022. The annual report can be accessed on the Company's investor relations website at https://ir.genenta.com/financial-information/sec-filings as well as the SEC's website at http://www.sec.gov.

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

No dose limiting toxicity observed in previous three dose level cohortsRepresents a 50% higher dose than highest prior levelUpdate of guidance for trial

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

Initial evidence of potential to modulate tumor microenvironment Initial evidence of potential to modulate tumor microenvironment

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

35 years industry experience including as CEO and founder of public company

Genenta Announces Nomination of Mark A. Sirgo as Chair

*** David Reardon, Luigi Naldini, Brad Loncar *** *** David Reardon, Luigi Naldini, Brad Loncar ***

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Data to be presented at the 2022 annual meeting of American Association for Cancer Research Data to be presented at the 2022 annual meeting of American Association for Cancer Research

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

MILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that management will be participating in the following upcoming investor conferences:

News for Genenta Science S.P.A. Stock (GNTA)